【24h】

Extracorporeal photopheresis in prevention and treatment of acute GVHD

机译:体外光透疗法在急性GVHD的预防和治疗中

获取原文
获取原文并翻译 | 示例
           

摘要

Acute graft versus host disease (GVHD), a common complication after allogeneic hematopoietic cell transplantation (HCT), occurs in as many as 70% of recipients of this life saving treatment. Front line therapy for GVHD with corticosteroids will fail in up to 40% of patients, which leads to high morbidity and mortality. Traditional prevention and treatment strategies have focused on reducing alloreactivity, typically with therapy to reduce cytotoxic T-cell function. Emerging evidence exists that promotion of regularly T-cell function, through treatments such as extracorporeal photopheresis, is effective for GVHD treatment and has potential for prevention as well. This review will focus on literature reporting the success of ECP for steroid refractory acute GVHD and the potential for delivery of ECP in the early pre and post-transplant periods that shows promise as a less immunosuppressive strategy to reduce rates of acute GVHD. (C) 2015 Published by Elsevier Ltd.
机译:急性移植物抗宿主病(GVHD)是同种异体造血细胞移植(HCT)后的常见并发症,这种救命治疗的接受者多达70%。糖皮质激素治疗GVHD的一线治疗最多可导致40%的患者失败,从而导致较高的发病率和死亡率。传统的预防和治疗策略集中于减少同种异体反应,通常采用减少细胞毒性T细胞功能的疗法。越来越多的证据表明,通过体外光透疗法等疗法促进正常的T细胞功能对GVHD治疗有效,并且也具有预防的潜力。这篇综述将侧重于文献报道的ECP对于类固醇难治性急性GVHD的成功以及在移植前和移植后早期交付ECP的潜力,这显示出有望作为降低急性GVHD发生率的免疫抑制策略。 (C)2015由Elsevier Ltd.出版

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号